FULC FY 2020 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M

Gross Profit

-$50M-569.2% margin

Operating Income

-$72M-811.6% margin

Net Income

-$71M-802.7% margin

EPS (Diluted)

$-2.70

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$130M

Total Liabilities

$34M

Stockholders' Equity

$95M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$0	—
Gross Profit	-$50M	-$2M	-2346.1%
Operating Income	-$72M	-$59M	-22.1%
Net Income	-$71M	-$83M	+14.3%